Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION (Use several sheets if necessary)	Applicants Neil T. Parkin and Rainer A. Ziermann	
	Filing Date January 19, 2001	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
SH		5 7 6 6 8 4 2	6/16/98	Melnick, et al. **(Exhibit 1);**	435	5	
SH		5 8 3 7 4 6 4	11/17/98	Capon, et al. **(Exhibit 2);**	435	6	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH		International Search Report for the PCT Application No. PCT/US00/17178, filed June 22, 2000 with the U.S. Receiving Office **(Exhibit 3);**
		Dreyer GB, et al. (1993) "A Symmetric Inhibitor Binds HIV-I Protease Asymmetrically" Biochemistry **32:**937-947 **(Exhibit 4);**
		J. Eron, et al., (1995) Preliminary Assessment of 141W94 in Combination with Other Protease Inhibitors", 5th Conference on Retroviruses and Opportunistic Infections: 6 **(Exhibit 5);**
		Hill, A. et al. (1998) "Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar", Int. Conf. AIDS **12:812,** (Abstract No. 6) **(Exhibit 6);**
SH		E.E. Kim, (1995) " Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme", J. Am. Chem. Soc., 117: 1181-1182 **(Exhibit 7);**

EXAMINER	DATE CONSIDERED
[signature]	1/11/2

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants Neil T. Parkin and Rainer A. Ziermann	
	Filing Date January 19, 2001	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Lambert DM, et al. (1992) "Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells" Anit Microb Agents Chem 36:982-988 **(Exhibit 8)**;
		Brendan A. Larder, et al., (1995) "Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy", Science, 269; 696-699 **(Exhibit 9)**;
		Janis K. Lazdins, et al., (1997) "In Vitro Effect of α_1-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study with Other Relevant HIV Protease Inhibitors", J Infec. Dis., 175: 1063-1070 **(Exhibit 10)**;
		David J. Livingston, et al., (1995) "Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy", J Infec. Dis., 172:1238-1245 **(Exhibit 11)**;
		Bhuvaneshwari Mahalingam, et al., (1999) "Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease", Biochem., 263: 1-9 **(Exhibit 12)**;

EXAMINER	DATE CONSIDERED
	1/11/2

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Neil T. Parkin and Rainer A. Ziermann	
	Filing Date: January 19, 2001	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SFF		Miller M, et al. (1989) "Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 A Resolution" Science **246**:1149-1152 **(Exhibit 13)**;
		Mohri H, et al. (1993) "Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients", PNAS **90**:25-29 **(Exhibit 14)**;
		Robert L. Murphy, et al., (1999) "Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection" J. Infec. Dis., 179: 808-816 **(Exhibit 15)**;
		Nájera I, et al. (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates", Aids Res Hum Retroviruses **10**:1479-1488, **(Exhibit 16)**;
SFF		Nájera I, et al. (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in Virus From Patients Undergoing No Drug Therapy", J Virol **69**:23-31 **(Exhibit 17)**;

EXAMINER	DATE CONSIDERED
	1/11/2

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants Neil T. Parkin and Rainer A. Ziermann	
	Filing Date January 19, 2001	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH		Sarah Palmer, et al., (1999) "Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compounds in Current Clinical Development", AIDS, 13: 661-667 **(Exhibit 18)**;
		Neil T. Parkin, et al., (1999) "Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy", J Infec. Dis., 180: 865-870 **(Exhibit 19)**;
		Judith A. Partaledis, et al., (1995) "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease", Journal of Virology, 69: 5228-5235 **(Exhibit 20)**;
		A. K. Patick, et al., (1998) "Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir", Antimicrobial Agents and Chemotherapy, 42: 2637-2644 **(Exhibit 21)**;
SH		Petit SC, et al. (1993) "The Specificity of the HIV-1 Protease" Drug Discov Des 1:69-83 **(Exhibit 22)**;

EXAMINER	DATE CONSIDERED
	1/11/2

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants Neil T. Parkin and Rainer A. Ziermann	
	Filing Date January 19, 2001	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Roberts NA, et al. (1990) "Rational Design of Peptide-Based HIV Proteinase" Science **248**:358-361 **(Exhibit 23);**
		Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors", AIDS.**9** (supp 2) S27-S32 **(Exhibit 24);**
		Brian M. Sadler, et al., (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults", Antimicrobial Agents and Chemotherapy, 43: 1686-1692 **(Exhibit 25);**
		Sarkar G. and Sommer SS., (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis", BioTech **8(4)**:404-407 **(Exhibit 26);**
		Mary L. Smidt, et al., (1996) "A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside the Active Site, Confers Resistance to the Hydroxyethylurea Inhibitor SC-55389A", Antimicrobial Agents and Chemotherapy, 41: 515-522 **(Exhibit 27);**
		M. H. St. Clair, et al., (1996) "In Vitro Antiviral Activity of 141W94 (VX-478) in Combination with Other Antiretroviral Agents", Antiviral Research 29: 53-56 **(Exhibit 28);**

EXAMINER	DATE CONSIDERED
	1/11/2

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 59597-D/JPW/AJM/CMR	Serial No. 09/766,344
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants Neil T. Parkin and Rainer A. Ziermann	
	Filing Date January 19, 2001	Group Art Unit

OIPE JC53 SEP 24 2001 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SHF		H. Tian, et al., (1998) "Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity", 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30: **(Exhibit 29)**;
		Tisdâle, M. et al. (1998): "Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy", Int. Conf AIDS **12**:583 (Abstract No. 32312) **(Exhibit 30)**;
		Simon P. Tucker, et al., (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro", Antimicrobial Agents and Chemotherapy, 42: 478-480 **(Exhibit 31)**;
		Young, B. et al., (1998) "Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J. Infectious Disease, **178**: 1497-1501 **(Exhibit 32)**; and
SHF		Rainer Ziermann, et al., (in press May 2000) "A Mutation in HIV-1 Protease, N-88S, that Causes In Vitro Hypersensitivity to Amprenavir", J Virol., 74: 4414-4419 **(Exhibit 33)**.

EXAMINER	DATE CONSIDERED
	1/4/2

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.